StockNews.AI
CV
StockNews.AI
28 days

CapsoVision Announces Closing of Initial Public Offering

1. CapsoVision closed its IPO, raising $27.5 million with $5.00 per share price. 2. Shares of CapsoVision began trading on Nasdaq under ticker symbol 'CV'. 3. Underwriters have a 30-day option for additional share purchases. 4. CapsoVision focuses on AI and imaging solutions for gastrointestinal diseases. 5. Future products include non-invasive colon imaging and polyp detection.

6m saved
Insight
Article

FAQ

Why Bullish?

The successful IPO and raised capital can support future growth. Similar IPOs in med-tech indicate potential for stock price increase.

How important is it?

The IPO indicates strong market interest and potential for growth, thus impacting investor sentiment.

Why Long Term?

With successful funding, CapsoVision can invest in R&D for innovative products, boosting market position over time.

Related Companies

MDGLNVCRTMCI
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $27.5 million. The Benchmark Company, LLC and Roth Capital Partners acted as joint book-running managers for the offering. A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering was made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at prospectus@benchmarkcompany.com This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CapsoVisionCapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com. Forward-Looking StatementsThis press release contains or may contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, and other risks described in the Company’s registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law. Investor Relations ContactLeigh SalvoNew Street Investor RelationsInvestors@CapsoVision.com Kevin LundquistChief Financial Officer, CapsoVision, Inc.kml@capsovision.com Media ContactLeslie Strickler and Paul SpicerÊtre Communicationsleslies@etrecommunications.com | (804) 240-0807pauls@etrecommunications.com | (804) 503-9231

Related News